Search results

Jump to navigation Jump to search

Page title matches

  • ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Nesiritide is considered adjunctive therapy for patients in severe heart failure, prin
    2 KB (299 words) - 21:01, 2 March 2010
  • 121 bytes (15 words) - 20:41, 2 March 2010
  • 281 bytes (37 words) - 20:45, 2 March 2010

Page text matches

  • #REDIRECT [[Nesiritide]]
    24 bytes (2 words) - 20:38, 2 March 2010
  • ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Nesiritide is considered adjunctive therapy for patients in severe heart failure, prin
    2 KB (299 words) - 21:01, 2 March 2010
  • {{r|Nesiritide}}
    279 bytes (30 words) - 00:30, 3 March 2010
  • ...12124404&promo=ONFLNS19 |issn=}}</ref> A recombinant DNA version of BNP, [[nesiritide]] (trade name Natrecor), is also given as a treatment for heart failure. ==Treatment with nesiritide==
    11 KB (1,470 words) - 14:35, 18 March 2024
  • ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J
    13 KB (1,669 words) - 07:45, 9 June 2014
  • ...retic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J
    73 KB (10,150 words) - 21:46, 20 August 2014